The patient with evolving acute MI should receive early intravenous -adrenergic blocker therapy, followed by oral therapy, provided that there is no contraindication. -Adrenoceptor blocker therapy should be initiated regardless of whether reperfusion therapy was given, because several studies in the prethrombolytic as well as the thrombolytic era showed that -adrenoceptor blockers diminish morbidity and mortality.